Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis

Neridronate: From Experimental Data to Clinical Use

“…A significant reduction in the serum CTX levels was observed 2 months after the first neridronate infusion. 39 These results were confirmed in another pilot randomized study evaluating the effects of 25 mg of neridronate administered monthly for 12 months on 20 women with post-menopausal osteoporosis compared with 20 control subjects who were treated with the placebo. The spine and hip BMDs were significantly increased in the treated patients compared with those in the placebo patients (+6.6% ± 3% and 4.2% ± 2.3%, respectively), and markers of bone turnover were significantly decreased after 3 months of neridronate treatment and progressively decreased during the observation period.…”

Acute Pseudogout Following Intravenous Neridronate for Osteoporosis

“…Other investigations were unremarkable, except for low 25-OH vitamin D levels (22.1 ng/ml) and elevated plasma parathyroid hormone (144 pg/ml). She was then diagnosed with osteoporosis, supplemented with 300,000 IU of oral cholecalciferol, and started therapy with neridronic acid (NA), 100 mg intravenously 1 . Corticosteroids had been tapered before starting NA.…”

Intravenous bisphosphonate therapy for osteoporosis: Where do we stand?

“…A few studies [63][64][65] suggest some benefit, but the available data are less impressive than the findings with other agents. Neridronate 50 mg intravenously every 2 months produced significant increases in bone mineral density and decreases in bone turnover markers in a 2-year placebo-controlled trial [66].…”